Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress
CAMBRIDGE, Mass. and BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced a poster presentation at the European Hematology Association (EHA) Congress being held June 9-12, 2022. The poster will review initial clinical data from the Company’s ongoing Phase 2 APEX trial with bezuclastinib. The abstract is available on the EHA website at www.ehaweb.org and the poster will be published on the EHA Congress platform on June 10, 2022.
Presentation Title: A Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V inhibitor, in Adults with Advanced Systemic Mastocytosis (Apex): Methods, Baseline Data, and Early Insights
About Cogent Biosciences, Inc.